Mehdi Loukhnati, Benjamin Hebraud, Marine Cazaux, Cécile Borel, Pierre Bories, Jean Alain Martignoles, Miguel Granell, Pierre Cougoul, Jeremie Dion, Lucie Oberic, Anne Huynh, Illias Tazi, Aurore Perrot
{"title":"Outpatient Rescue With Stem Cells Boost for Refractory Hematotoxicity Following anti-BCMA CAR T-Cell Therapy: A Case Report.","authors":"Mehdi Loukhnati, Benjamin Hebraud, Marine Cazaux, Cécile Borel, Pierre Bories, Jean Alain Martignoles, Miguel Granell, Pierre Cougoul, Jeremie Dion, Lucie Oberic, Anne Huynh, Illias Tazi, Aurore Perrot","doi":"10.1155/crh/1558475","DOIUrl":null,"url":null,"abstract":"<p><p>Prolonged and refractory hematotoxicity is a severe complication of anti-BCMA CAR-T cell therapy, associated with substantial morbidity. When conventional supportive measures (transfusions and hematopoietic growth factors) fail, alternative strategies are urgently needed. We report the case of a 55-year-old man who developed persistent cytopenias after idecabtagene vicleucel. Reinfusion of cryopreserved autologous stem cells (stem cell boost), administered without conditioning chemotherapy, resulted in rapid and complete hematopoietic recovery after 14 days. This case highlights the potential of stem cell boost as a salvage approach for prolonged post-CAR-T hematotoxicity and underscores the need for prospective multicenter studies to standardize indications, timing, and procedures for this intervention.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2026 ","pages":"1558475"},"PeriodicalIF":0.7000,"publicationDate":"2026-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13238238/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/crh/1558475","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Prolonged and refractory hematotoxicity is a severe complication of anti-BCMA CAR-T cell therapy, associated with substantial morbidity. When conventional supportive measures (transfusions and hematopoietic growth factors) fail, alternative strategies are urgently needed. We report the case of a 55-year-old man who developed persistent cytopenias after idecabtagene vicleucel. Reinfusion of cryopreserved autologous stem cells (stem cell boost), administered without conditioning chemotherapy, resulted in rapid and complete hematopoietic recovery after 14 days. This case highlights the potential of stem cell boost as a salvage approach for prolonged post-CAR-T hematotoxicity and underscores the need for prospective multicenter studies to standardize indications, timing, and procedures for this intervention.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
